BackNovavax Overview

Novavax Total Assets

Track Novavax's total assets ($1B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$1.04B
↓ 19.32% YoYΔ $-249.83M vs prior year quarter

Peer average

Loading

Novavax Total Assets History

Loading

Novavax vs. peers: Total Assets Comparison

Loading

Novavax Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Novavax (NVAX) FAQ

As of the most recent data (March 2026), NVAX shows a total assets of $1B. That compares with $1.3B in the prior-year period — down 19.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVAX's total assets is now $1B (was $1.3B) — a 19.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Novavax is outperforming or lagging.

Tracking NVAX's total assets over time shows whether Novavax is scaling, shrinking, or reshaping that part of the business. The current reading is $1B That compares with $1.3B in the prior-year period — down 19.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Novavax's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $1B) with ownership activity and broader fundamentals.

Novavax's total assets is $1B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.